Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Epstein-Barr_virus
|
| gptkbp:affects |
nasopharynx
|
| gptkbp:associated_with |
weight loss
dysphagia chronic sinusitis nasopharyngeal lymphoid tissue |
| gptkbp:caused_by |
gptkb:Epstein-Barr_virus
|
| gptkbp:clinical_trial |
studies on combination therapies
ongoing research for new therapies investigating biomarkers research on genetic predisposition trials for novel drug delivery systems |
| gptkbp:end_of_life |
varies by stage
overall 5-year survival rate is around 60-70% |
| gptkbp:genetic_diversity |
T P53
PI K3 CA CDK N2 A |
| https://www.w3.org/2000/01/rdf-schema#label |
nasopharyngeal carcinoma
|
| gptkbp:is_popular_in |
more common in males
higher in Southeast Asia |
| gptkbp:number_of_stages |
Stage I
Stage II Stage III Stage IV |
| gptkbp:risk_factor |
family history
smoking exposure to certain chemicals |
| gptkbp:screenings |
gptkb:MRI
CT scan nasopharyngoscopy |
| gptkbp:social_responsibility |
biopsy
depends on stage early detection improves outcomes common in young adults and middle-aged individuals more prevalent in males than females |
| gptkbp:symptoms |
headaches
nasal obstruction ear pain swelling in the neck |
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine palliative care supportive care radiation therapy chemotherapy targeted therapy adjuvant therapy neoadjuvant therapy radiotherapy techniques chemoradiation |